2nd APACC – Presentations

  Plenairy session 1: Opening session
Chairs: Adeeba Kamarulzaman, Annette Sohn, Charles Boucher & Patrick Li
 
Key note lecture: HIV/AIDS in the Asia Pacific: Where is the Epidemic Heading?
Dr. C. Beyrer, John Hopkins University, Center for AIDS Research, USA
 
Program implementer perspective
Dr. F. Zhang, Beijing Ditan Hospital, Capital Medical University, China
 
Community Perspective
Dr. M. Choo, Kuala Lumpur AIDS Support Services Society (KLASS), Malaysia
  Parallel session 1: Emerging ART management paradigms - Are 2 drugs enough?
Chairs: David Cooper & Nagalingeswaran Kumarasamy
 
ART: are two drugs enough?
Dr. M. Boyd, The Kirby Institute, University of New South Wales, Australia
 
The SWORD study
Dr. C.C.Hung, National Taiwan University College of Medicine, Taiwan
  Abstract presentations
 Treatment-emerged adverse events and health-related quality of life in HIV-infected patients after stable switch from boosted protease inhibitors to Raltegravir: A multicenter, cohort study (coming soon)
Dr. S.S.J. Lee, Kaohsiung Veterans General Hospital, Taiwan
 Efficacy and safety of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir alafenamide (E/C/F/TAF) in virologically suppressed asian adults with renal impairment
Dr. B. Chin, National Medical Center/Center for Infectious Diseases, South Korea
  Parallel session 2: Opportunistic Infections
Chairs: Nicholas Paton & Thomas Man-Kit
 
What’s new in the management of fungal opportunistic infections (not available)
Dr. T. Le, Oxford University Clinical Research Unit, the Hospital for Tropical Diseases, Vietnam
 
Identifying TB co-infection - new approaches
Dr. C. Chuchottaworn, Central Chest in Nonthaburi, Thailand
  Abstract presentations
 Cost effectiveness of a screening program for Cryptococcal antigenemia among antiretroviral naive HIV infected patients with CD4< 100 cell/cumm in a referral HIV care center at Mysore, South India
Dr. S. Rama, Asha Kirana Hospital, India
 Acute Shigellosis among HIV-infected people in 2015: An outbreak investigation
Dr. Y.T. Shen, Centers for Disease Control, Taiwan
 HIV care in Yangon, Myanmar; successes, challenges and implications for policy
Dr. J. Hanson, The Kirby Institute, University of New South Wales, Australia
  Parallel session 3: Point of Care testing
Chairs: Hongzhou Lu & Shinichi Oka
 
Innovative ways to stimulate the demand of HIV and HCV testing
Dr. P. Cunningham, The Kirby Institute, University of New South Wales, Australia
  Abstract presentations
 The clinical utility of the urine based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: a prospective, hospital-based study
Dr. J. Hanson, The Kirby Institute, University of New South Wales, Australia
 HIV prevalence in men who have sex with men in Shinjuku 2-chome gay town, Tokyo: Result from the HIV testing program using the home collection kit
Dr. M. Takano, National Center for Global Health and Medicine, Japan
 HIV testing as the bridge between awareness and acceptance of PrEP among MSM
Dr. T.H. Kwan, Jockey Club School of Public Health and Primary Care, Hong Kong
  Plenairy session 2: Challenges in Long-term HIV care
Chairs: Annette Sohn & Evy Yunihastuti
 
Mental health and neurocognitive issues related to adolescents who have grown up with HIV
Dr. W. Ng, Columbia University Medical Center, USA
 
Aging among adults in the context of HIV
Dr. R. Rajasuriar, University of Malaya, Malaysia
 
Neurocognitive issues among aging adults
Dr. E. Wright, Alfred Health & Burnet Institute, Australia
  Parallel session 4: Treatment Failure & Resistance
Chairs: Jonathan Schapiro & Jun Yong Choi
 
Does resistance still matter?
Dr. D. Kuritzkes, Harvard Medical School, USA
 
Resistance testing for selecting second line drugs (coming soon)
Dr. N. Paton, National University of Singapore, Singapore
 
Clinical Case presentation
Dr. C. C. Hung, National Taiwan University College of Medicine, Taiwan
  Abstract presentations
 The emergence of transmitted protease inhibitor resistance mutations in adults starting antiretroviral therapy in northern Vietnam
Dr. T. Le, Oxford University Clinical Research Unit, the Hospital for Tropical Diseases, Vietnam
 Highly automated deep sequencing-based HIV-1 drug resistance monitoring system
Dr. E. Rakhmanaliev, Vela Diagnostics, Singapore
  Parallel session 5: Hepatitis HIV Co-infection
Chairs: Ching-Lung Lai & Tsang Tak Yin
 
Outbreak of hepatitis A among HIV-infected men who have sex with men in Hong Kong (not available)
Dr. C.K.B. Wong, Special Preventive Programme, Centre for Health Protection, Department of Health, Hong Kong
 
HIV and intestinal co-infections (coming soon)
Dr. I.F.N. Hung, The University of Hong Kong, Hong Kong
  Abstract presentations
 High-risk behaviour in a cohort of HIV/hepatitis C coinfected gay and bisexual men commencing hepatitis C treatment (not available)
Dr. J. Dole, Burnet Institute, Australia
 Suitability of HCV treatment in primary care settings for individuals with HIV/hepatitis C coinfection (not available)
Dr. J. Dole, Burnet Institute, Australia
 Treatment of patients with chronic hepatitis C genotype 3 infection with or without cirrhosis with sofosbuvir and daclatasvir therapy (coming soon)
Dr. O. Goyal, Dayanand Medical College and Hospital, Country
 Drug interactions between anti-HCV Antivirals Ledipasvir/Sofosbuvir and integrase strand transfer inhibitor-based regimens
Dr. D. Mccoll, Gilead Sciences Inc., Singapore
  Parallel session 7: Key populations
Chairs: Chris Beyrer & Annette Sohn
 
HIV and adolescents: How do we help them to prepare for adult life
Dr. R. Lolekha, Thailand Ministry of Public Health-U.S. CDC Collaboration, Thailand
  Abstract presentations
 Transition into adult care: Factors associated with level of preparedness among adolescents living with HIV in Cambodia
Dr. S. Yi, Khana Center for Population Health Research, Cambodia
 Increase new case detection of HIV among MSM and TG through PDI+ (coming soon)
Dr. K. So, Khmer HIV/AIDS NGO Alliance (KHANA), Cambodia
 Factors associated with HIV infection among transgender women in Cambodia: Results from a national integrated biological and behavioral survey
Dr. S. Yi, Khana Center for Population Health Research, Cambodia
 Gender difference in compliance with self-deferral for blood donation on HIV-related risk (not available)
Dr. K.H. Cheung, Stanley Ho Centre for Emerging Infectious Diseases, Hong Kong
  Parallel session 8: Comorbidities (non-AIDS related)
Chairs: Adeeba Kamarulzaman & Man-Po Lee
 
Renal disease and HIV
Dr. S. Pujari, Institute of Infectious Diseases, India
 
Cardiovascular disease and HIV
Dr. S. Sungkanuparph, Ramathibodi Hospital, Mahidol University, Thailand
  Abstract presentations
 Assessment of atherosclerotic cardiovascular disease (ASCVD) risks between HIV-infected patients receiving first-line and second-line antiretroviral therapy
Dr. J. Tiarukkitsagul, Ramathibodi Hospital, Mahidol University, Thailand
 Higher burden of chronic comorbidities among aged hospitalized HIV patients compared to non-HIV infected patients in Japan
Dr. D. Ruzicka, MSD K.k., Japan
 Prevalence of sarcopenia and associated risk factors among HIV-infected individuals receiving suppressive antiretroviral therapy
Dr. R. Rajasuriar, University of Malay, Malaysia
 Social support plays a critical role in enhancing mental health among HIV-infected patients in Hanoi, Vietnam (not available)
Dr. M. Shoko, National Center for Global Health and Medicine, Japan
  Parallel session 9: Innovative HIV testing, prevention and care service delivery models
Chairs: Margaret Hellard & Joe Tucker
 
Recruiting people into HIV Services: eBooking
Dr. P. Na Nakorn, Thai Red Cross AIDS Research Centre, Thailand
 
Online platforms to spur HIV testing
Dr. J. Tucker, University of North Carolina, School of Medicine, USA
 
e-Cascade for real-time monitoring of HIV program
Dr. M. Avery, FHI 360 Bangkok, Thailand
  Abstract presentations
 Consideration regarding the service model on pre-exposure prophylaxis for men who have sex with men in the community
Dr. T.H. Kwam, Jockey Club School of Public Health and Primary Care, Hong Kong
 Pre-exposure prophylaxis uptake among men who have sex with men at a clinic in Bangkok, Thailand, 2016
Dr. W. Wimonsate, Thailand Ministry of Public Health - U.S. CDC Collaboration, Thailand
 Using a robust incentive-based, peer-centered model to identify new HIV cases among men who have sex with men, transgender women, and people who inject drugs in Cambodia
Dr. R. Sopha, Khmer HIV/AIDS NGO Alliance (KHANA), Cambodia
  Plenairy session 3: Implementation of PrEP
Chairs: Nittaya Phanuphak & Fujie Zhang
 
Population-based PrEP implementation in New South Wales, Australia
Dr. A. Grulich, The Kirby Institute, University of New South Wales, Australia
 
Round Table Discussion: True demand from the communities
Dr. M. Poonkasetwattana, Asia Pacific Coalition on Male Sexual Health, Thailand
 
Round Table Discussion: Genuine supply from the providers
Dr. R. Ditangco, Research Institute for Tropical Medicine, Philippines
 
PrEP research and implementation gaps
Dr. M. Cassell, USAID, Thailand
  Plenairy session 4: Access to hepatitis C treatment in the region
Chairs: Jürgen Rockstroh & Hsi-Hsun Lin
 
Access to treatment/care on the global level
Dr. M. Hellard, Burnet Institute, Australia
 
Access to treatment/care on the country level
Dr. G. Khwairakpam, TREAT Asia, Thailand
 
Barriers to access - Community perspective
Dr. M. Choo, Kuala Lumpur AIDS Support Services Society (KLASS), Malaysia
  Plenairy session 5: New drugs on the Horizon
Chairs: Charles Boucher & Patrick Li
 
New HIV drugs / regimens
Dr. D. Kuritzkes, Harvard Medical School, USA
 
New hepatitis drugs
Dr. J. Rockstroh, University of Bonn, Germany
 
New TB drugs (coming soon)
Dr. N. Paton, National University of Singapore, Singapore